The Alpha-1 Alliance is campaigning for the establishment of a highly specialised service for Alpha-1 patients. As future patient access to a licensed augmentation therapy will be an integral part of this service, we warmly welcome the augmentation therapy clinical trial results recently presented by CSL Behring at the American Thoracic Society conference and their intention to apply for market authorisation in the UK.
CSL Behring has made a commitment to patients in the UK and has provided a donation in support of the Alpha-1 Alliance campaign. We are extremely grateful for this support which will allow us to implement our rigorous campaign plan for the next 12 months. This will include a number of campaigning activities over the course of the next year, such as the development of a policy report, further meetings with politicians and a Patient Day in Parliament.
We will be engaging with NHS England and the Department of Health in the coming months to further define the next steps of the process to secure a new highly specialised service, and will provide regular updates on the progress of the campaign.
Editorial: The Alpha-1 Alliance includes the Alpha-1 UK Support Group, Alpha-1 Awareness UK and Alpha-1 Advocacy and Action and is chaired by Dr Ravi Mahadeva, representing the clinical community.